M+W Group Receives Major Contract for Merck's New Pharmaceutical Facility in China
M+W Group has been awarded a major order from Merck for its new pharmaceutical facility in China. The site with around 40,000 squaremeters is located in the Nantong Economical Technological Development area in the Greater Shanghai region. M+W Group will be responsible for the engineering design, procurement, construction management and validation services of the factory including production and support buildings.
The new facility is designed to manufacture multiple types of dry forms of Oral Solid Dosage (OSD) in their final packaging for the Chinese market, with focus on Merck's leading brands for the treatment of diabetes, cardiovascular diseases and thyroid disorders. Production capacity is planned to reach over two billion tablets per year in the first phase, going operational by the end of 2016. The total building area has about 38,000 squaremeters, with the production building (23,000 squaremeters) as well as the warehouse and logistics building (9,000 squarementers) taking up the most space. Both are dedicated to high level cGMP (current Good Manufacturing Practice) activities. Other buildings will house the central utilities, the fire fighting pump station, canteen and offices.
Dr. Olaf Berlien, CEO of M+W Group, about this new order: "We are pleased that this new pharmaceutical facility will not only strengthen Merck's presence in China, but will also contribute to covering China's growing healthcare needs in important areas like diabetes, cardiovascular diseases and thyroid disorders."
Other news from the department business & finance
